- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ARRIVENT BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| Do | ArriVent BioPharma: Goldman Sachs startet Coverage mit "Buy"-Rating | 2 | Investing.com Deutsch | ||
| 03.07. | ArriVent BioPharma stock maintains Buy rating at Clear Street despite competitor approval | 1 | Investing.com | ||
| 02.07. | ArriVent BioPharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.07. | ArriVent BioPharma prices $75M equity offering | 1 | Seeking Alpha | ||
| 02.07. | ArriVent BioPharma, Inc.: ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| 01.07. | ArriVent BioPharma kündigt öffentliches Angebot von 75 Millionen US-Dollar an | 2 | Investing.com Deutsch | ||
| 01.07. | ArriVent BioPharma announces $75 million public offering | 2 | Investing.com | ||
| 01.07. | ArriVent announces $75M public offering | 1 | Seeking Alpha | ||
| 01.07. | ArriVent BioPharma, Inc.: ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| 30.06. | ArriVent BioPharma-Aktie behält Kaufempfehlung von H.C. Wainwright nach starken NSCLC-Studiendaten | - | Investing.com Deutsch | ||
| 30.06. | ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright on strong NSCLC trial data | 1 | Investing.com | ||
| 24.06. | Clear Street stuft ArriVent BioPharma-Aktie mit Kaufempfehlung ein | 2 | Investing.com Deutsch | ||
| 24.06. | Clear Street initiates ArriVent BioPharma stock with Buy rating | 3 | Investing.com | ||
| 23.06. | Citi erhöht Kursziel für ArriVent BioPharma nach positiven Lungenkrebsdaten | 3 | Investing.com Deutsch | ||
| 23.06. | Citi raises ArriVent BioPharma stock price target on lung cancer data | 3 | Investing.com | ||
| 23.06. | ArriVent reports 16-month progression-free survival for lung cancer drug | 3 | Investing.com | ||
| 23.06. | ArriVent berichtet über 16-monatiges progressionsfreies Überleben bei Lungenkrebs-Medikament | 2 | Investing.com Deutsch | ||
| 23.06. | ArriVent BioPharma, Inc.: ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study | 155 | GlobeNewswire (Europe) | 16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients Robust central nervous system (CNS) activity; 41%... ► Artikel lesen | |
| 20.06. | ArriVent BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.06. | ArriVent BioPharma, Inc.: ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC | 2 | GlobeNewswire (USA) |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PROKIDNEY | 5,210 | 0,00 % | Pre-market Movers: Basel Medical Group, SOBR Safe, ProKidney, RxSight, Mustang Bio | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.05 A.M. ET).In the Green Basel Medical Group Ltd (BMGL) is up over 88% at... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,715 | 0,00 % | Recursion Pharmaceuticals: Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia | Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition... ► Artikel lesen | |
| BEAM THERAPEUTICS | 22,000 | 0,00 % | H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT | ||
| COGENT BIOSCIENCES | 10,840 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced ... | -- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared... ► Artikel lesen | |
| NURIX THERAPEUTICS | 12,680 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 25,890 | 0,00 % | Summit Therapeutics vor Mega-Deal: Aktie +15% | Papiere von Summit Therapeutics legen heute in der Spitze um +15% zu. Vorausgegangen ist ein Bloomberg-Bericht um einen bevorstehenden Mega-Deals mit dem Pharmakonzern AstraZeneca. Laut Bloomberg News... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 31,460 | +0,61 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,470 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 38,540 | 0,00 % | Apogee Therapeutics: Kurssturz trotz Super-Daten! | Apogee Therapeutics liefert positive Studiendaten zu einem potenziellen Milliarden-Medikament. Doch nach anfänglicher Euphorie im vorbörslichen Handel wird die Aktie abverkauft. Vielversprechende 16-Wochen-Daten... ► Artikel lesen | |
| PRIME MEDICINE | 4,680 | 0,00 % | Prime Medicine soars as Jones sees it as an acquisition target | ||
| HARMONY BIOSCIENCES | 34,330 | +0,12 % | SUSANNAH CONSTANTINE, 63, CHOOSES THE NEW ALMA HARMONY BIO-BOOST FOR MID-LIFE SKIN CONFIDENCE | *The Next Generation Collagen Laser Facial for glowing, smoother, firmer skin*
The author, podcaster and TV personality Susannah Constantine, 63, opens up about confidence, ageing, and... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 15,280 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 50,32 | 0,00 % | Piper Sandler reiterates Overweight rating on Praxis Precision Medicines stock | ||
| COGNITION THERAPEUTICS | 0,700 | 0,00 % | Cognition Therapeutics, Inc.: Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease | PURCHASE, N.Y., July 10, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders... ► Artikel lesen | |
| QIAGEN | 41,380 | -1,25 % | Biotech Report: Qiagen geben ab, Evotec behauptet | (shareribs.com) Frankfurt / New York 07.07.2025 - Biotech-Aktie bewegten sich im deutschen Handel überwiegend nach unten. Qiagen verloren. An der Wall Street kommt es zu Kursverlusten. Auch der Biotech-Sektor... ► Artikel lesen |
ARRIVENT BIOPHARMA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 22,010 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARRIVENT BIOPHARMA INC finden Sie auf Wallstreet Online.